| FORM 4 | 4 |
|--------|---|
|--------|---|

| Check this box if no |
|-----------------------|
| longer subject to |
| Section 16. Form 4 or |
| Form 5 obligations |
| may continue. See |
| Instruction 1(b). |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Respons | es) | | - | | | | | | | | | |
|--|---------|--|---|--------------------|--------|---|------------------|--|---|----------------------------------|---|--|
| (Last) (First) (Middle) OPKO HEALTH, INC., 4400 BISCAYNE BLVD. | | | 2. Issuer Name a Opko Health, Is | nc. [OPK |] | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) —X_DirectorX_10% Owner X_Officer (give title below)Other (specify below) | | | |
| | | | 3. Date of Earlies 02/27/2013 | t Transacti | on (N | /lonth/Day | y/Year) |) | | | | |
| | | | 4. If Amendment, | Date Orig | inal I | Filed(Mont | h/Day/Ye | 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person | | | | |
| MIAMI, FL 33137 | (24-4-) | (7:-) | | | | | | | _X_Form filed by More than One Reporting | | | |
| (City) | (State) | (Zip) | Ta | | | | | • | red, Disposed of, or Beneficially | | | |
| 1.Title of Security (Instr. 3) | | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | Ownership Form: | 7. Nature of Indirect Beneficial Ownership | |
| | | | | Code | v | Amount | (A) or (D) | Price | | or Indirect (I) (Instr. 4) | (Instr. 4) | |
| Common Stock | | 02/27/2013 | | Р | | 8,600 | А | \$ 7.0225 | 120,985,854 | I | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 13,900 | А | \$ 7.03 | 120,999,754 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 5,400 | А | \$ 7.04 | 121,005,154 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 400 | А | \$ 7.05 | 121,005,554 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 200 | A | \$ 7.06 | 121,005,754 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 6,300 | А | \$ 7.07 | 121,012,054 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 47 | А | \$ 7.08 | 121,012,101 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 800 | А | \$ 7.09 | 121,012,901 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 8,353 | А | \$ 7.1 | 121,021,254 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 500 | А | \$ 7.1198 | 121,021,754 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 5,000 | A | \$ 7.1207 | 121,026,754 | Ι | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 4,700 | А | \$ 7.1304 | 121,031,454 | I | See Footnote (1) | |
| Common Stock | | 02/27/2013 | | Р | | 800 | А | \$ 7.14 | 121,032,254 | Ι | See Footnote (1) | |
| Common Stock | | | | | | | | | 15,490,546 | I | See Footnote (2) | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

| (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
|--|-------------|------------------|--------------------|------------|----|--------|-------|--------------|--------------------|--------|---------|-------------|----------------|-------------|-------------|
| 1. Title of | 2. | 3. Transaction | 3A. Deemed | 4. | | 5. Nu | mber | 6. Date Exer | rcisable | 7. Tit | tle and | 8. Price of | 9. Number of | 10. | 11. Nature |
| Derivative | Conversion | Date | Execution Date, if | Transacti | on | of | | and Expirati | on Date | Amo | unt of | Derivative | Derivative | Ownership | of Indirect |
| Security | or Exercise | (Month/Day/Year) | any | Code | | Deriv | ative | (Month/Day | /Year) | Unde | rlying | Security | Securities | Form of | Beneficial |
| (Instr. 3) | Price of | | (Month/Day/Year) | (Instr. 8) | | Secur | ities | | | Secu | rities | (Instr. 5) | Beneficially | Derivative | Ownership |
| | Derivative | | | | | Acqu | ired | | | (Insti | : 3 and | | Owned | Security: | (Instr. 4) |
| | Security | | | | | (A) o | r | | | 4) | | | Following | Direct (D) | |
| | | | | | | Dispo | sed | | | | | | Reported | or Indirect | |
| | | | | | | of (D) |) | | | | | | Transaction(s) | (I) | |
| | | | | | | (Instr | | | | | | | (Instr. 4) | (Instr. 4) | |
| | | | | | | 4, and | 15) | | | | | | | | |
| | | | | | | | | | | | Amount | | | | |
| | | | | | | | | Date | Expiration | | or | | | | |
| | | | | | | | | Exercisable | Expiration Date | Title | Number | | | | |
| | | | | | | | | Excretisable | Date | | of | | | | |
| | | | | Code | V | (A) | (D) | | | | Shares | | | | |

Reporting Owners

| | | Relationships | | | | | | | | |
|---|---|---------------|-----------|----------------|-------|--|--|--|--|--|
| | Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | | | | |
| 2 | FROST PHILLIP MD ET AL OPKO HEALTH, INC. 4400 BISCAYNE BLVD. MIAMI, FL 33137 | Х | Х | CEO & Chairman | | | | | | |
| 4 | Frost Gamma Investments Trust 4400 BISCAYNE BLVD. MIAMI, FL 33137 | | Х | | | | | | | |

Signatures

| Phillip Frost, M.D., Individually and as Trustee | 02/28/2013 |
|--|------------|
| Signature of Reporting Person | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole (1) shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- These securities are owned directly by The Frost Group, LLC. Frost Gamma Investments Trust is a principal member of The Frost Group, LLC. The reporting person (2) disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

JOINT FILER INFORMATION

Name: Frost Gamma Investments Trust

Address: 4400 Biscayne Blvd. Miami, FL 33137

Designated Filer: Phillip Frost, M.D.

Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)

Date of Earliest Transaction: February 27, 2013

Relationship to Issuer: 10% Owner

FROST GAMMA INVESTMENTS TRUST

By: /s/ Phillip Frost, M.D., as Trustee Phillip Frost, M.D., Trustee